Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Voyager Therapeutics (VYGR) Revenue (2016 - 2025)

Voyager Therapeutics' Revenue history spans 11 years, with the latest figure at $15.3 million for Q4 2025.

  • For Q4 2025, Revenue rose 144.28% year-over-year to $15.3 million; the TTM value through Dec 2025 reached $40.4 million, down 24.4%, while the annual FY2025 figure was $40.4 million, 49.53% down from the prior year.
  • Revenue for Q4 2025 was $15.3 million at Voyager Therapeutics, up from $13.3 million in the prior quarter.
  • Across five years, Revenue topped out at $150.5 million in Q1 2023 and bottomed at -$1.5 million in Q4 2022.
  • The 5-year median for Revenue is $6.4 million (2024), against an average of $21.1 million.
  • The largest annual shift saw Revenue plummeted 105.52% in 2022 before it surged 22769.3% in 2023.
  • A 5-year view of Revenue shows it stood at $28.1 million in 2021, then crashed by 105.52% to -$1.5 million in 2022, then surged by 5910.39% to $90.1 million in 2023, then plummeted by 93.03% to $6.3 million in 2024, then surged by 144.28% to $15.3 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Revenue are $15.3 million (Q4 2025), $13.3 million (Q3 2025), and $5.2 million (Q2 2025).